All Type 2 diabetes articles
-
On demand webinarsReal-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)
This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer. View prescribing information Video: 20200723 Takeda hosted webinar Click here to complete the feedback and receive your CPD certificate ...
-
Hosted content
Case study on Type 2 diabetes management: implementation of a DPP-4 inhibitor switch strategy across a primary care network
This advertorial has been commissioned and developed by Takeda UK Ltd. View prescribing information Information intended for healthcare professionals only. If the PDF does not load within 5 seconds, please refresh the page Case study on Type 2 diabetes management: implementation of ...
-
Implementing guidelines
Diagnose and treat pancreatic exocrine insufficiency in diabetes
Dr Kate Millar and Professor Michael Cummings present a summary of guidance that aims to help practitioners to identify and manage pancreatic exocrine insufficiency in people with diabetes
-
Animation
Prescribing a dipeptidyl peptidase-4 inhibitor in people with type 2 diabetes and comorbidities
This animation has been commissioned and funded by Boehringer Ingelheim Limited and developed in partnership with Guidelines in Practice . Boehringer Ingelheim Limited suggested the topic and the presenter, and carried out full medical approval on all materials to ensure compliance with regulations. The sponsorship fee included an honorarium ...
-
Checklist
Implementing the clinical guideline on pancreatic exocrine insufficiency in diabetes
Supported by an arm’s-length educational grant from Mylan.
-
Supplement
Switching appropriate patients with type 2 diabetes to alogliptin from existing DPP-4 inhibitors: experience and outcomes from three Clinical Commissioning Groups and Local Health Boards
Information for healthcare professionals only. This supplement has been commissioned and funded by Takeda UK Ltd, it has been developed in partnership with Grey Bear Consultancy and published by Guidelines in Practice . Please see bottom of page for full disclaimer. View prescribing information ...
-
Sponsored algorithm
Dipeptidyl peptidase-4 inhibitors: the different dosing requirements of adult patients with type 2 diabetes and comorbidities
This management algorithm has been commissioned and funded by Boehringer Ingelheim Limited.
-
Test and reflect
Patient scenarios: diabetes and cardiovascular risk
The following scenarios are fictitious but similar to those experienced by real patients and are designed to help you reflect on what you have learnt after reading the article. They could also be used for group discussion in an education or practice meeting. There are no right or wrong answers ...
-
Supplement
Guideline for the managed introduction of biosimilar basal insulin
Guidelines identified a need for clinical guidance in a specific area and approached Mylan for an educational grant to support the development of a working party guideline. This working party guideline was developed by Guidelines , and the Chair and members of the group were chosen by and convened ...
-
Test and reflect
Collaborative stakeholder initiative for the management of type 2 diabetes in older people
This CPD activity consists of 3 multiple-choice questions (MCQs) designed to test your knowledge on the management of diabetes in older people, including in the context of frailty.
-
Implementing guidelines
Type 2 diabetes: targets and treatments should be person-centred
Dr Clare Hambling and Dr Patrick Holmes highlight the key recommendations from the joint ADA/EASD consensus report on the management of hyperglycaemia in type 2 diabetes
-
Pharmacist focus
Type 2 diabetes: the role of the practice pharmacist
Muhammad Siddiqur Rahman highlights the integral role of practice-based pharmacists in managing type 2 diabetes
-
Test and reflect
Best practice in managing co-morbidities in type 2 diabetes
This CPD activity consists of 5 multiple-choice questions (MCQs) designed to test your knowledge on managing the co-morbidities of type 2 diabetes—you will then be prompted to reflect on your learning.
-
Co-morbidities in ...
Co-morbidities in type 2 diabetes
Dr Kevin Fernando describes eight common co-morbidities in patients with type 2 diabetes and how the co-existing conditions should be managed
-
Test and reflect
SIGN guideline on pharmacological management of type 2 diabetes
This CPD activity consists of 5 multiple-choice questions (MCQs) designed to test your knowledge on SIGN guideline recommendations on managing type 2 diabetes—you will then be prompted to reflect on your learning.
-
Implementing guidelines
Type 2 diabetes: what are the benefits and risks of glucose-lowering agents?
Dr Kevin Fernando explains how SIGN 154 offers evidence-based guidance on glucose control therapies for people with type 2 diabetes
-
News
SIGN updates diabetes guidance
The Scottish Intercollegiate Guidelines Network has updated its guidance on the management of diabetes and published new guidance on pharmacological management of glycaemic control in people with type 2 diabetes.
-
Test and reflect
NICE guideline on type 2 diabetes
This CPD activity consists of 4 multiple-choice questions (MCQs) designed to test your knowledge on type 2 diabetes in adults—you will then be prompted to reflect on your learning.
-
News
NICE updates guidance on type 2 diabetes prevention
NICE has published an update to NICE Public Health Guideline 38 on Type 2 diabetes: prevention in people at high risk .
-
Top tips
Top tips: type 2 diabetes
Dr Kevin Fernando provides top tips on diagnosing and managing type 2 diabetes and identifying people at high risk
